Skip to Content
Merck
  • Hepatocyte-specific deletion of Pparα promotes NAFLD in the context of obesity.

Hepatocyte-specific deletion of Pparα promotes NAFLD in the context of obesity.

Scientific reports (2020-04-18)
Marion Régnier, Arnaud Polizzi, Sarra Smati, Céline Lukowicz, Anne Fougerat, Yannick Lippi, Edwin Fouché, Frédéric Lasserre, Claire Naylies, Colette Bétoulières, Valentin Barquissau, Etienne Mouisel, Justine Bertrand-Michel, Aurélie Batut, Talal Al Saati, Cécile Canlet, Marie Tremblay-Franco, Sandrine Ellero-Simatos, Dominique Langin, Catherine Postic, Walter Wahli, Nicolas Loiseau, Hervé Guillou, Alexandra Montagner
ABSTRACT

Peroxisome proliferator activated receptor α (PPARα) acts as a fatty acid sensor to orchestrate the transcription of genes coding for rate-limiting enzymes required for lipid oxidation in hepatocytes. Mice only lacking Pparα in hepatocytes spontaneously develop steatosis without obesity in aging. Steatosis can develop into non alcoholic steatohepatitis (NASH), which may progress to irreversible damage, such as fibrosis and hepatocarcinoma. While NASH appears as a major public health concern worldwide, it remains an unmet medical need. In the current study, we investigated the role of hepatocyte PPARα in a preclinical model of steatosis. For this, we used High Fat Diet (HFD) feeding as a model of obesity in C57BL/6 J male Wild-Type mice (WT), in whole-body Pparα- deficient mice (Pparα-/-) and in mice lacking Pparα only in hepatocytes (Pparαhep-/-). We provide evidence that Pparα deletion in hepatocytes promotes NAFLD and liver inflammation in mice fed a HFD. This enhanced NAFLD susceptibility occurs without development of glucose intolerance. Moreover, our data reveal that non-hepatocytic PPARα activity predominantly contributes to the metabolic response to HFD. Taken together, our data support hepatocyte PPARα as being essential to the prevention of NAFLD and that extra-hepatocyte PPARα activity contributes to whole-body lipid homeostasis.

MATERIALS
Product Number
Brand
Product Description

Avanti
12:0 PE, 1,2-dilauroyl-sn-glycero-3-phosphoethanolamine, powder
Avanti
18:0 SM (d18:1/18:0), Avanti Research - A Croda Brand 860586P, powder
Avanti
16:0 PE, Avanti Research - A Croda Brand
Avanti
16:0 PC (DPPC), Avanti Research - A Croda Brand
Avanti
16:0 PC (DPPC), Avanti Research - A Croda Brand
Avanti
12:0 SM (d18:1/12:0), Avanti Research - A Croda Brand 860583P, powder
Avanti
C18 Ceramide (d18:1/18:0), Avanti Research - A Croda Brand
Avanti
13:0 PC, 1,2-ditridecanoyl-sn-glycero-3-phosphocholine, chloroform
Avanti
13:0 PC, 1,2-ditridecanoyl-sn-glycero-3-phosphocholine, powder